Trial Profile
Pharmacokinetic and safety study of sirolimus or everolimus combined with HCV direct acting antiviral agents (ombitasvir, paritaprevir/r and dasabuvir) in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Apr 2017
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Everolimus; Sirolimus
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- 02 Apr 2017 New trial record
- 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics